莱博瑞辰完成A++轮融资，百洋医药集团领投

Core Viewpoint - Zhongshan Leberich Biopharmaceutical Co., Ltd. has successfully completed an A++ round of financing, exceeding its fundraising target, with participation from several investors including Baiyang Pharmaceutical Group, Dongfang Morning Star, Saint No Biotech, and Chenghai Venture Capital [1] Group 1 - The financing round was led by Baiyang Pharmaceutical Group, with follow-on investments from Dongfang Morning Star, Saint No Biotech, and Chenghai Venture Capital [1] - Existing shareholder Zhuhai Yihai also increased its investment in this round [1] - The funds raised will primarily be used to advance pipeline projects RAB001d and RAB202, as well as to strengthen the company's technology platform and team development [1]